ABI announced its plans to invest in the company, which is developing next-generation sequencing technology, in October.
ABI has also entered into a scientific collaboration with VisiGen.
Financial terms of the transaction was not disclosed, although ABI's investment hinged on a follow-on investment from VisGen shareholder SeqWright.
SeqWright announced that it had made a second equity investment, of an undisclosed amount, in November.